IntelGenx’s Anti-Depressant, CPI-300, Receives FDA Approval
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Blog
VisionCare’s FDA Approved Telescope Gets Implanted
VisionCare’s lead product, Implantable Miniature Telescope by Dr. Isaac Liphitz, enlarges images in front of the eye approximately 2.5 times their normal size.
PLC Medical Systems Uses Revenue in the EU to Fund Phase III Development in the US
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
Hepregen Corp. Introduces Toxicity Screening Platform
Hepregen is focused on improving and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies.
Special Panels Present Significant Opportunity at OneMedForum SF 2012
Panels consisting of leading strategic and financial investors will be followed by short presentations by promising companies. Over 100 companies will present.
Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Avita Medical’s ReCell Achieves Breakthrough in Leg Ulcer Treatment
Avita Medical announces that ReCell has demonstrated a very high success rate in the treatment of chronic leg ulcers.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
STR, Inc. Advances its ACL Treatment Technology after Receiving $750K in Funding from Connecticut Innovations
The product, L-C Ligament, is considered a breakthrough in the treatment of ACL tears.
Cytomedix Allows Global Pharma Company Exclusivity to Chronic Wound Healing Technology
Cytomedix announced the implementation of a letter agreement allowing an undisclosed global pharmaceutical company an exclusivity period.